Charles Schwab Investment Management Inc Tarsus Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

$557 Billion
Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 329,297 shares of TARS stock, worth $23.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

329,297

Previous 290,318 13.43%

Holding current value

$23.4 Million

Previous $14.9 Million 10.55%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$39.88 - $51.49 $1.55 Million - $2.01 Million	38,979 Added 13.43%	329,297 $13.3 Million
Q1 2025 Sep 15, 2025	SELL	$41.29 - $56.94 $1.61 Million - $2.22 Million	-38,979 Reduced 11.84%	290,318 $14.9 Million
Q1 2025 May 09, 2025	SELL	$41.29 - $56.94 $139,642 - $192,571	-3,382 Reduced 1.15%	290,318 $14.9 Million
Q4 2024 Feb 06, 2025	BUY	$32.27 - $55.37 $119,108 - $204,370	3,691 Added 1.27%	293,700 $16.3 Million
Q3 2024 Nov 12, 2024	BUY	$21.54 - $34.6 $605,920 - $973,298	28,130 Added 10.74%	290,009 $9.54 Million
Q2 2024 Aug 12, 2024	BUY	$25.17 - $38.73 $1 Million - $1.54 Million	39,882 Added 17.97%	261,879 $7.12 Million
Q1 2024 May 08, 2024	BUY	$19.61 - $39.22 $65,399 - $130,798	3,335 Added 1.53%	221,997 $8.07 Million
Q4 2023 Feb 06, 2024	BUY	$12.98 - $20.73 $392,878 - $627,455	30,268 Added 16.07%	218,662 $4.43 Million
Q3 2023 Nov 08, 2023	BUY	$14.75 - $24.62 $527,017 - $879,672	35,730 Added 23.4%	188,394 $3.35 Million
Q2 2023 Aug 09, 2023	BUY	$11.57 - $19.63 $156,345 - $265,260	13,513 Added 9.71%	152,664 $2.76 Million
Q1 2023 May 11, 2023	BUY	$11.92 - $16.27 $7,152 - $9,762	600 Added 0.43%	139,151 $1.75 Million
Q4 2022 Feb 13, 2023	BUY	$14.12 - $18.72 $30,654 - $40,641	2,171 Added 1.59%	138,551 $2.03 Million
Q3 2022 Nov 14, 2022	BUY	$14.08 - $18.5 $614,549 - $807,469	43,647 Added 47.07%	136,380 $2.34 Million
Q2 2022 Aug 15, 2022	BUY	$11.08 - $19.08 $489,182 - $842,381	44,150 Added 90.88%	92,733 $1.35 Million
Q1 2022 May 13, 2022	BUY	$14.49 - $24.28 $20,314 - $34,040	1,402 Added 2.97%	48,583 $818,000
Q4 2021 Feb 11, 2022	BUY	$21.21 - $29.68 $8,802 - $12,317	415 Added 0.89%	47,181 $1.06 Million
Q3 2021 Nov 16, 2021	BUY	$21.45 - $29.22 $4,139 - $5,639	193 Added 0.41%	46,766 $1.01 Million
Q2 2021 Aug 16, 2021	BUY	$27.16 - $38.59 $134,442 - $191,020	4,950 Added 11.89%	46,573 $1.35 Million
Q1 2021 May 17, 2021	BUY	$27.37 - $47.25 $120,428 - $207,900	4,400 Added 11.82%	41,623 $1.34 Million
Q4 2020 Feb 16, 2021	BUY	$19.17 - $49.62 $713,564 - $1.85 Million	37,223 New	37,223 $1.54 Million

Others Institutions Holding TARS

# of Institutions

214

Shares Held

46.7M

Call Options Held

7.8K

Put Options Held

View Full List

About Tarsus Pharmaceuticals, Inc.

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $1.9B
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

More about TARS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Tarsus Pharmaceuticals, Inc. Transaction History